Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination

We intended to assess the humoral response induced by the Pfizer/BioNTech Comirnaty COVID-19 vaccine with commercially available immunoassays: anti-spike (S) IgG and IgM, and anti-nucleocapsid (N) IgG antibodies, over a 4-month course. One hundred subjects, including 15 COVID-19 convalescents, compr...

Descripción completa

Detalles Bibliográficos
Autores principales: Swadźba, Jakub, Anyszek, Tomasz, Panek, Andrzej, Martin, Emilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617658/
https://www.ncbi.nlm.nih.gov/pubmed/34835298
http://dx.doi.org/10.3390/vaccines9111367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617658/
https://www.ncbi.nlm.nih.gov/pubmed/34835298
http://dx.doi.org/10.3390/vaccines9111367

Ejemplares similares